Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines designed to reach intracellular targets that have historically been difficult to access. Its approach centers on Endosomal Escape Vehicle technology, which supports a development pipeline of genetic medicine candidates aimed at neuromuscular and inherited retinal diseases. The company’s preclinical programs include ENTR-601-44, ENTR-601-45, and VX-670. Founded in 2016 and formerly known as CycloPorters, Inc., Entrada Therapeutics adopted its current name in October 2017 and is headquartered in Boston, Massachusetts. The company’s common stock trades on NASDAQ under the symbol TRDA.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TRDA
|
$7.26
|
13.3% Upside
|
Fair
|
$18.75
|
192.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-1.4x
|
0.9x
|
40.8x
|
228.5 M
|
29.109 M
|
17.9%
|
59.4%
|
0.0
|
—
|
79.2%
|
